China's M&A landscape may be too rich for acquisitive multinationals
This article was originally published in Clinica
Executive Summary
Medtech multinationals that are looking to grow their presence in China through acquisitions of local players could find themselves struggling to get a good deal. Not only do buyers have to contend with the usual issues of finding the right assets that meet their specific strategic objectives, but the current climate in the Chinese financial markets means potential targets won’t come cheap.